Nicorandil is a small molecule KATP (Kir6) channel opener, producing relaxation of coronary vascular smooth muscle. Specific binding of Nicorandil to the C-terminus of the SUR2B K(ATP) channel generates K+ flux and hyperpolarization of the surface membrane, producing consequent closure of voltage-dependent ion channels and reduction of intracellular free Ca2+. Nicorandil stimulates guanylate cyclase and increases cyclic GMP levels in correlation with the activation of K(ATP) channels. Nicorandil is also described to suppress mitochondrial permeability transition triggered by oxidative stress resulting from ischemia-reperfusion, preventing mitochondrial calcium uptake/overload and oxidative damage. Nicorandil has also been shown to serve as a nitric oxide donor.
1. Kukovetz, W R., et al., 1992. Molecular mechanism of action of nicorandil. Journal of cardiovascular pharmacology. 20 Suppl 3(): S1-7. PMID: 1282168
2. Yoneyama, F., et al., 1990. Nicorandil increases coronary blood flow predominantly by K-channel opening mechanism. Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy. 4(4): 1119-26. PMID: 2150593
3. Miyazaki, Y., et al., 1985. Vasodilative effect of nicorandil on coronary artery. Arzneimittel-Forschung. 35(2): 504-7. PMID: 3158319
4. Haeusler, G., et al., 1994. Therapeutic potential of potassium channel activators in coronary heart disease. European heart journal. 15 Suppl C(): 82-8. PMID: 7995277
5. Shindo, T., et al., 1998. SUR2 subtype (A and B)-dependent differential activation of the cloned ATP-sensitive K+ channels by pinacidil and nicorandil. British journal of pharmacology. 124(5): 985-91. PMID: 9692785
6. Horinaka, Shigeo., et al., 2004. Nicorandil protects against lethal ischemic ventricular arrhythmias and up-regulates endothelial nitric oxide synthase expression and sulfonylurea receptor 2 mRNA in conscious rats with acute myocardial infarction. Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy. 18(1): 13-22. PMID: 15115899
7. Fujiwara, Takayuki., et al., 2007. Nicorandil suppresses the increases in plasma level of matrix metalloproteinase activity and attenuates left ventricular remodeling in patients with acute myocardial infarction. Heart and vessels. 22(5): 303-9. PMID: 17879021
8. Carreira, Raquel S., et al., 2008. Nicorandil protects cardiac mitochondria against permeability transition induced by ischemia-reperfusion. Journal of bioenergetics and biomembranes. 40(2): 95-102. PMID: 18415669
See how others have used Nicorandil. Click on the entry to view the PubMed entry .
PMID: # 25932125 Kong, JJ. et al. 2015. Int J Clin Exp Med. 8: 1966-75.
PMID: # 18415669 Carreira, RS. et al. 2008. J. Bioenerg. Biomembr. 40: 95-102.
PMID: # 9692785 Shindo, T. et al. 1998. Br. J. Pharmacol. 124: 985-991.
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.